ATE464321T1 - Gentherapie des auges - Google Patents

Gentherapie des auges

Info

Publication number
ATE464321T1
ATE464321T1 AT03790928T AT03790928T ATE464321T1 AT E464321 T1 ATE464321 T1 AT E464321T1 AT 03790928 T AT03790928 T AT 03790928T AT 03790928 T AT03790928 T AT 03790928T AT E464321 T1 ATE464321 T1 AT E464321T1
Authority
AT
Austria
Prior art keywords
choroidal neovascularization
eye
gene therapy
vivo
individual
Prior art date
Application number
AT03790928T
Other languages
English (en)
Inventor
Peter Campochiaro
Michael Kaleko
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31978303&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE464321(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE464321T1 publication Critical patent/ATE464321T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT03790928T 2002-08-28 2003-08-27 Gentherapie des auges ATE464321T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40647002P 2002-08-28 2002-08-28
PCT/EP2003/009497 WO2004020469A2 (en) 2002-08-28 2003-08-27 Ocular gene therapy

Publications (1)

Publication Number Publication Date
ATE464321T1 true ATE464321T1 (de) 2010-04-15

Family

ID=31978303

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03790928T ATE464321T1 (de) 2002-08-28 2003-08-27 Gentherapie des auges

Country Status (11)

Country Link
US (1) US20070104684A1 (de)
EP (1) EP1534751B1 (de)
JP (1) JP4612417B2 (de)
CN (2) CN100526332C (de)
AT (1) ATE464321T1 (de)
AU (1) AU2003258675B2 (de)
CA (1) CA2496820A1 (de)
DE (1) DE60332122D1 (de)
IL (1) IL166950A (de)
NZ (1) NZ538958A (de)
WO (1) WO2004020469A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100475270C (zh) * 2006-01-20 2009-04-08 清华大学 一种治疗肿瘤的药物及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6174861B1 (en) 1996-10-22 2001-01-16 The Children's Medical Center Corporation Methods of inhibiting angiogenesis via increasing in vivo concentrations of endostatin protein
CA2304983A1 (en) * 1997-09-24 1999-04-01 The Regents Of The University Of California Non-primate lentiviral vectors and packaging systems
US6106826A (en) * 1997-12-17 2000-08-22 Wisconsin Alumni Research Foundation Replication competent, avirulent Herpes simplex virus as a vector for neural and ocular gene therapy
US6670321B1 (en) * 1998-12-30 2003-12-30 The Children's Medical Center Corporation Prevention and treatment for retinal ischemia and edema
US6267954B1 (en) * 1999-11-24 2001-07-31 Universite De Paris V Rene-Descartes Intraocular transplantation of encapsulated cells
EP1280929A2 (de) * 2000-05-01 2003-02-05 Novartis AG VEKTOREN FüR AUGENSTRANSDUKTION UND IHRE VERWENDUNGEN FüR DIE GENETISCHE BEHANDLUNG
US20020077289A1 (en) * 2000-06-02 2002-06-20 Macdonald Nicholas J. Angiostatin and endostatin binding proteins and methods of use
WO2002030982A2 (en) * 2000-10-13 2002-04-18 Entremed, Inc. Endostatin and pitslre protein kinases as angiogenesis-inhibiting peptides and method of use
US20020183253A1 (en) * 2001-02-22 2002-12-05 Brazzell Romulus Kimbro Method of treating ocular neovascularization
CA2475101A1 (en) * 2002-02-04 2003-08-14 Novartis Ag Recombinant bovine immunodeficiency virus based gene transfer system
JP2006506321A (ja) * 2002-04-11 2006-02-23 チルドレンズ メディカル センター コーポレーション 血管透過性亢進を阻害する方法
US20060251621A1 (en) * 2002-09-27 2006-11-09 Campochiaro Peter A Ocular gene therapy

Also Published As

Publication number Publication date
US20070104684A1 (en) 2007-05-10
IL166950A (en) 2011-04-28
WO2004020469A2 (en) 2004-03-11
CN100526332C (zh) 2009-08-12
AU2003258675A1 (en) 2004-03-19
HK1077306A1 (en) 2006-02-10
NZ538958A (en) 2006-09-29
WO2004020469A3 (en) 2004-04-29
CN101637611A (zh) 2010-02-03
EP1534751A2 (de) 2005-06-01
JP4612417B2 (ja) 2011-01-12
EP1534751B1 (de) 2010-04-14
AU2003258675B2 (en) 2009-03-26
DE60332122D1 (de) 2010-05-27
CA2496820A1 (en) 2004-03-11
JP2006516112A (ja) 2006-06-22
CN1708513A (zh) 2005-12-14

Similar Documents

Publication Publication Date Title
MX2010003774A (es) Formulaciones oftalmicas acuosas.
EA201001695A1 (ru) Применение эпотилона d для лечения заболеваний, связанных с тау-белком
TW200633709A (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions
DE602007013391D1 (de) Cyclosporins zur behandlung und vorbeugung von augenerkrankungen
BRPI0516377A (pt) inibição de rnai de ctgf para tratamento de distúrbios oculares
WO2002067971A3 (en) Use of endostatin in the treatment of ocular neovascularization
EA200901211A1 (ru) Антигены белка с5 и их применение
WO2005076998A3 (en) Rnai therapeutics for treatment of eye neovascularization diseases
TW200502385A (en) Modulation of forkhead box o1a expression
ES2674129T3 (es) Agentes terapéuticos de base aptámeros útiles en el tratamiento de trastornos relacionados con complemento
MY137053A (en) Pyrimidine derivatives and their use as cb2 modulators
ATE531383T1 (de) Therapeutische verwendung eines wachstumsfaktors, metrnl
TW200833341A (en) 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions
ATE445415T1 (de) Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung
MX2011013060A (es) Formulaciones oftalmicas, metodos de preparacion y metodos para utilizarlas.
WO2021174107A3 (en) Soluble ace2 variants and uses therefor
EP4124346A3 (de) Zusammensetzungen und verfahren zur behandlung von krankheiten
WO2008067040A3 (en) Method of detecting ocular diseases and pathologic conditions and treatment of same
EP2401648A4 (de) Verwendung von orthokeratologischen linsen in kombination mit einer chemischen behandlung zur korrektur von kurzsichtigkeit, weitsichtigkeit oder astigmatismus
TW200611695A (en) Pyrrolopyridine derivatives
GB0416508D0 (en) Therapeutic agents
NO20063716L (no) Anvendelse av lavdose erytropoietin ved stimulering av endotel forloperceller, regenerering av organer og sinking av progresjonen av sluttorganskader
MXPA05008561A (es) Uso de esteroides para tratar personas que sufren de trastornos oculares.
WO2004024089A3 (en) Inhibition or activation of adam9 and adam15 for treatment of vascularization-related disease and wound healing
ATE496992T1 (de) Behandlung von igai-ablagerungserkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties